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1422Objectives: Bronchiolitis obliterans (BO) is a severe complication limiting long-term survival after lung trans-
plantation. To date, no cure exists for BO, and the mechanisms leading to BO are not well understood.
Endothelin-1 (ET-1) is a potent mitogenic and profibrotic peptide produced by pulmonary vascular endothelial
cells that play a role in the pathophysiology of lung allograft dysfunction. Whether ET-1 could predict BO syn-
drome (BOS) development is unknown.
Methods: Transbronchial biopsy specimens and serum and bronchoalveolar lavage were obtained from 30 lung
transplantation patients with and 30 without BOS at 3 points. The serum and bronchoalveolar lavage ET-1 con-
centrations were measured by enzyme-linked immunosorbent assay, and the ET-1 mRNA expression in the
transbronchial biopsy specimens was examined using real-time polymerase chain reaction.
Results: The pretransplant ET-1 serum concentrations were greater in the patients with BOS (P¼ .02); and ET-1
mRNA was significantly upregulated in the lung grafts of those with versus those without BOS at 3 and 12
months after transplant (P ¼ .01). At 3 and 12 months after transplantation, the ET-1 concentrations were sig-
nificantly elevated in the serum (P<.01 and P<.0001, respectively) and bronchoalveolar lavage (P<.01 and
P ¼ .02, respectively) of patients with compared with those without BOS. On logistic regression analysis, the
pretransplant and 3-month post-transplant serum ET-1 level predicted for BOS (odds ratio, 1.01; 95% confi-
dence interval, 1.004–1.025; P<.007; odds ratio, 2.9; 95% confidence interval, 1.01–8.52; P<.001). The serum
ET-1 level at 12 months was diagnostic for BOS (odds ratio, 3.9; 95% confidence interval, 1.42–10.80;
P ¼ .008).
Conclusions: Elevated serum ET-1 concentrations were predictive of BOS, and the assessment of circulating
ET-1 might be beneficial in diagnosing and monitoring BO. (J Thorac Cardiovasc Surg 2010;140:1422-7)Bronchiolitis obliterans syndrome (BOS) remains the major
cause of late graft loss in lung transplant recipients.1 BOS
affects 18% to 57% of lung allograft recipients within the
first 5 years after transplantation. It also accounts for more
than 30% of all deaths after the third post-transplant
year.1,2 Histologically, BOS is characterized by obliterative
bronchiolitis and, physiologically, by deterioration of
pulmonary function and a decrease in the forced expiratory
volume in 1 second (FEV1).
3,4 Although the FEV1 is the
main diagnostic tool of BOS, transbronchial biopsy (TBB)
remains the reference standard. However, TBB is invasive
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The Journal of Thoracic and Cardiovascular Surpulmonary function. More importantly, obtaining tissue by
TBB that will allow a conclusive diagnosis of BO might
be problematic. Also, false-negative histologic results can
occur despite the declining pulmonary function.
The pathogenesis of BOS remains unclear, although
repeated injury to the allograft by ischemia reperfusion,
acute rejection, inflammation, alloreactivity directed toward
HLA antigens and infections, particularly cytomegalovirus
(CMV) infection, havebeen thought to contribute toBOSde-
velopment.3,5 These assaults are followed by responsive
neutrophil and lymphocyte infiltration of the allograft, with
secondary activation of various cytokines and chemokines,
which contribute to inflammatory cell infiltration and BOS
progression.6 Endothelin (ET)-1 is one of themain cytokines
and is expressed in the endothelium, smooth muscle cells,
airway epithelium, and alveolar macrophages of the lung.7
Evidence has suggested that ET-1 is involved in many pul-
monary diseases, including pulmonaryfibrosis8 and acute re-
spiratory distress syndrome.9 Moreover, studies using
animalmodels have indicated that ET-1might have an effect
on the development of BO.10,11
Wehave previously reported that ET-1mediates increased
vascular permeability and edema formation in lung
grafts before reperfusion and primary graft dysfunction,gery c December 2010
Abbreviations and Acronyms
BAL ¼ bronchoalveolar lavage
BO ¼ bronchiolitis obliterans
BOS ¼ bronchiolitis obliterans syndrome
CI ¼ confidence interval
CMV ¼ cytomegalovirus
ET-1 ¼ endothelin-1
FEV1 ¼ forced expiratory volume in 1 second
OR ¼ odds ratio
PCR ¼ polymerase chain reaction
TBB ¼ transbronchial biopsy
Salama et al Cardiothoracic Transplantationa common risk factor for BOS.12,13 Others have shown that
antagonizing ET-1 in experimental lung transplantation
prevents fibrous airway obliteration.14 In the present study,
we addressed the utility of ET-1 in the prediction of BOS
development in lung transplant recipients.T
XPATIENTS AND METHODS
Patients
The ethics committee of the Medical University of Vienna approved the
present study. A total of 60 patients who had undergone lung transplanta-
tion between 2006 and 2009 and who have given informed consent to par-
ticipate were enrolled. The demographic data and the most relevant
characteristics of the patients are listed in Table 1. The serum samples
were obtained shortly before transfer to the operating room. Moreover,
TBB, serum, and bronchoalveolar lavage (BAL) samples were obtained
at 3 and 12 months after transplantation during routine clinical follow-up.
All samples were coded and snap frozen. All patients were routinely fol-
lowed upweekly in the first 3weeks,monthly during the first year, and every
2 months for the second year after transplantation, or when clinically indi-
cated. The surveillance protocol involved the patients’ history, physical sta-
tus, pulmonary function tests, blood tests, and bronchoscopy with BAL and
TBB. All TBB and BAL samples were examined histologically by an inde-
pendent pathologist.
BOS Diagnosis and Classification
The average of the 2 greatest pulmonary function measurements ob-
tained at least 3 weeks apart during the post-transplant course was used
to establish the baseline FEV1 and the forced expiratory flow at 25% to
75% of the vital capacity. BOS was then classified, according to the Inter-
national Society for Heart and Lung Transplantation Society guidelines15:
stage 0, FEV1 of 90% or more and forced expiratory flow at 25% to 75%
of the vital capacity of 75% or more; stage 0-p, FEV1 of 81% to 89%;
stage 1, FEV1 of 66% to 80%; stage 2, FEV1 51% to 65%; and stage 3,
FEV1 of less than 50%. Other causes of a decline in the FEV1 were ex-
cluded by bronchoscopy with TBB and BAL and high-resolution computed
tomography.
Diagnosis and Treatment of Rejection and Infection
Rejection was diagnosed histologically in the TBB samples and graded
according to the International Society for Heart and Lung Transplantation
scoring. Rejection was suspected clinically if patients had new radio-
graphic pulmonary opacification and deterioration of the blood gases and
pulmonary function without evidence of infection despite a TBB score of
A0 or B0 to B1. These patients underwent steroid pulse therapy at 1 g/The Journal of Thoracic and Card for 3 days. If the patient was resistant to the steroid pulse therapy,
muromonab-CD3 (OKT-3) was administered at 5 mg/d for 7 days. An ep-
isode of infection was defined clinically and approved usingmicrobiologic,
serologic, or histologic tests. CMV screening was performed by measure-
ment of CMV serology (quantitative polymerase chain reaction [PCR]) and
the detection of CMVearly antigen in blood, urine, throat smear, and BAL.
Bacterial and fungal cultures and PCR for toxoplasmosis and pneumocystis
carinii were performed in each BAL. The TBB specimens were also histo-
logically screened for CMV, pneumocystis carinii, toxoplasmosis, and bac-
terial or invasive fungal infection. Colonization was considered present if
the BAL microbiology was positive without histologic or clinical evidence
of infection.16
Immunosuppression
The immunosuppression protocol has been previously described.16 In
brief, the patients received 1 g methylprednisolone intraoperatively, fol-
lowed by 125 mg at 8, 16, and 24 hours postoperatively. Thereafter, pred-
nisolonewas administered at 1 mg/kg/d and tapered to 0.25 mg/kg within 3
months. All patients received rabbit-antithymocyte globulin (Thymoglobu-
lin; Sero-Merieux, Lyon, France) 2.5 mg/kg intravenously for the first 4
postoperative days. Mycophenolate mofetil (CellCept; Hoffmann-La
Roche, Basel, Switzerland) at 3 g/d was given intravenously on the first
postoperative day and then orally. Cyclosporine A (target level 350 ng/
mL) or tacrolimus (target level 15  3 ng/mL) was administered intrave-
nously immediately after surgery and subsequently switched to oral admin-
istration.
BOS Management
The treatment of patients with BOS was initiated after the diagnosis of
BOS from the pulmonary function test results when other causes of FEV1
decline had been excluded. Recipients with BOS received steroid bolus
therapy at 1000 mg/d for 3 days. Next, the steroid was reduced to
1 mg/kg within 2 weeks. The recipients then underwent pulmonary func-
tion testing and bronchoscopy every 2 weeks until stabilization. In the
case of BOS resistance, the immunosuppression regimen was changed
as follows. Cyclosporine A was switched to tacrolimus with a target se-
rum level of 18  2 ng/mL, depending on kidney function. If the switch
in immunosuppression was not effective, the steroid treatment was re-
peated. If this therapy failed, the patient received clarithromycin, rabbit
antithymocyte globulin (Thymoglobulin) or muromonab-CD3 (OKT-3),
as described in the ‘‘Diagnosis and treatment of rejection and infection’’
section.
Enzyme-Linked Immunosorbent Assay
An enzyme-linked immunosorbent assay for ET-1 (TiterZyme EIA, Cat-
alogueNo. 900–020;AssayDesigns,Minneapolis,Minn) was performed ac-
cording to the manufacturer’s protocol. Standard or serum samples were
added to each polyclonal ET-1 antibody precoated well and incubated at
4C overnight. The substrate reactionwas quantified spectrophotometrically
using a 96-well, automated microplate reader (Anthos, Salzburg, Austria) at
450 nm. The cross reactivity of the assay with other endothelin isotypes was
less than 0.1.13
Quantitative Real-Time Reverse Transcriptase PCR
Total RNAwas isolated from the TBB specimens with TRIzol (Invitro-
gen, Carlsbad, Calif), using MagNA Lyser (Roche, Mannheim, Germany).
Real-time reverse transcriptase PCR was performed on a LightCycler in-
strument (Roche), as previously described.13 The primer sequences were
sense/antisense: ET-1: 50-GGAAAAGACTGTTCCAAGC-30/50-GGTTG
TGGGTCACATAACG-30; and b2-microglobulin: 50-GATGAGTATGCCT
GCCGTGTG-30/50-CAATCCAAATGCGGCATCT-30. The expression of
the target gene was determined by relative quantification (ie, normalization
to the expression of the housekeeping gene, b2-microglobulin
13) anddiovascular Surgery c Volume 140, Number 6 1423
TABLE 1. Demographic and clinical characteristics of study patients
Characteristic All patients (n ¼ 60)
BOS
Grade 0 (n ¼ 30) Grade 1 (n ¼ 10) Grade 2 (n ¼ 10) Grade 3 (n ¼ 10)
Mean age (y) 50  15 49  16 54  14 53  14 51  14
Male gender (n) 32 (53%) 16 (53%) 5 (50%) 5 (50%) 6 (60%)
LTX type
SLTX 14 5 3 4 2
DLTX 46 25 7 6 8
Mean interval after LTX (mo) 12 12 12 12 12
Mean ischemic time (min) 320  41 318  42 315  23 340  71 341  63
Mechanical ventilation (d) 4 4 5 4 11*
ICU stay (d) 7 7 6 4 12*
FEV1 at discharge 54  24 58  24 50  22 48  19 34  26*
PGD (n) 25 (43%) 9 (30%) 5 (50%)y 5 (50%)y 6 (60%)y
Bacterial infection 12 8 0 3 1
Fungal infection 11 7 2 1 1
CMV infection 7 3 1 1 2
Immunosuppression
Tacrolimus/CyA 44/16 23/7 7/3 8/2 6/4
AR
A0 42 27 (90%) 7 (70%) 5 (50%) 3 (30%)z
A1 14 2 (7%) 3 (30%) 5 (50%)z 4 (40%)z
A2 2 1 (3%) 0 0 1 (10%)z
A3 2 0 0 0 2 (20%)z
B0 10 8 (27%) 0 1 (10%) 1 (10%)z
B1 34 19 (63%) 8 (80%) 3 (30%) 4 (40%)
B2 7 2 (7%) 1 (10%) 2 (20%)z 2 (20%)z
B3 9 1 (3%) 1 (10%)z 4 (40%)z 3 (30%)z
Incidence of AR/y 1.6  2.6 0.3  0.4 1.3  1.2 4.5  4.2z 4.8  3.7z
Temporal pattern of AR (wk) 2.7  2.4 1  1.3 2.6  2.1 3.4  1.7z 5.5  2.5z
BOS, Bronchiolitis obliterans syndrome; LTX, lung transplantation; SLTX, single LTX;DLTX, double LTX; ICU, intensive care unit; FEV1, forced expiratory volume in 1 s; PGD,
primary graft dysfunction; CMV, cytomegalovirus; CyA, cyclosporine A; AR, acute rejection. *P ¼ .02, yP ¼ .04, zP<.001 versus BOS grade 0.
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measurements was used for data analysis.
Statistical Analysis
All parameters were compared between the patient groups using the c2
test and analysis of variance (1-way analysis of variance; Tukey’s post hoc
test) according to the scale of the variable (categorical or continuous). The
associations between the serum and BAL ET-1 and the acute rejection ep-
isodes were analyzed using Spearman’s correlation coefficient. Repeated
measures-analysis of variancewas used to compare the repeated ET-1 mea-
surements at the 3 follow-up points. Multiple logistic regression analysis
was used to evaluate the confounder-adjusted effects of serum ET-1 to pre-
dict BOS, including all variables that were significant on univariate logistic
regression analyses at P ¼ .05. All statistical analyses were performed
using Statistical Analysis Systems for Windows, version 9.1.3, and the
Enterprise Guide, version 4.1 (SAS Institute, Inc, Cary, NC). Statistical
-significance was set at P<.05. The results are expressed as the mean 
standard deviation.RESULTS
Patient Clinical Characteristics
In our study cohort, 10 patients had BOS grade 3, 10 had
BOS grade 2, 10 had BOS grade 1, and 30 had no BOS
(grade 0) at 12 months after transplantation. The FEV1 at
discharge from the hospital was significantly lower in the1424 The Journal of Thoracic and Cardiovascular Surpatients with BOS grade 3 than in those without BOS (grade
0) (P ¼ .02; Table 1). The patients with BOS grade 3 re-
quired longer mechanical ventilation (P ¼ .02) and inten-
sive care unit stay (P ¼ .02) than those with grade 0.
Moreover, the patients with BOS grade 2 and 3 had signif-
icantly more acute rejection episodes than the patients with-
out BOS (P<.001; Table1). Moreover, the presence of BOS
grade 2 and 3 was associated with a significantly temporal
pattern of acute rejection episodes compared with BOS
grade 0 and 1 (P<.001; Table 1). Of note, BOS (grades 1
to 3) was significantly associated with primary graft dys-
function after lung transplantation (P¼ .04; Table 1). How-
ever, the frequency of CMV, bacterial, and fungal infections
was not significantly different between those with and with-
out BOS.Pretransplant Serum ET-1 Predicts BOS
Development
The pretransplant serum ET-1 levels were significantly
greater in patients who developed BOS grade 1 to 3
(P ¼ .02; Figure 1). However, no significant differences
were found when the BOS grades were comparedgery c December 2010
FIGURE 1. Pretransplant endothelin-1 (ET-1) serum concentrations were
elevated in patients who developed bronchiolitis obliterans syndrome
(BOS). Pretransplant serum ET-1 levels were significantly increased in
BOS grade 1 to 3 versus no BOS, although no significant differences
were found in ET-1 serum levels when BOS grades were compared.
*P ¼ .02.
FIGURE 2. Endothelin-1 (ET-1) mRNA expression levels were elevated
in lung tissue of patients with bronchiolitis obliterans syndrome (BOS).
ET-1 pulmonary tissue mRNA expression at 3 and 12 months (m.) after
transplant was resignificantly increased in BOS grades 1 to 3 versus with-
out BOS, although no significant differences were found in ET-1 mRNA
expression levels when BOS grades were compared. *P ¼ .01.
Salama et al Cardiothoracic Transplantation(P¼ .21). Logistic regression analysis revealed that the pre-
transplant serum ET-1 level predicted BOS development
(odds ratio [OR], 1.01; 95% confidence interval [CI],
1.004–1.025; P<.007; Table 2). Recipient age, graft ische-
mic time, duration of mechanical ventilation, intensive care
unit stay, FEV1 at discharge from the hospital did not pre-
dict for BOS (Table 2).TABLE 2. Logistic regression analysis
Variable
Univariate
OR (95% CI)
P
value
Adjusted
OR (95% CI)
P
value
Pretransplant
serum ET-1
1.01 (1.004–1.025) .007 _ _
Serum ET-1 at 3 mo 3.1 (1.21–9.92) .001 2.9 (1.01–8.52) .001
Serum ET-1 at 12 mo 3.9 (1.42–10.80) .008 3.5 (1.31–9.71) .007
AR
Grade A 6.8 (2.86–16.01) .001 5.1 (1.99–12.94) .001
Grade B 4.1 (2.28–7.54) .001 3.4 (1.82–6.72) .001
Age 1.01 (0.99–1.03) .35
Gender 0.96 (0.48–1.94) .96
Mechanical
ventilation
1.02 (0.93–1.11) .71
ICU stay 0.99 (0.92–1.08) .94
FEV1 at discharge 0.89 (0.73–1.11) .30
OR, Odds ratio; CI, confidence interval; ET-1, endothelin-1; other abbreviations as in
Table 1.
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XElevated Post-Transplant Serum ET-1 Predicts BOS
Development
The ET-1 mRNA expression levels in the TBB specimens
from patients with BOS (grade 1-3) were significantly
greater than the expression levels from the TBB specimens
of those without BOS at 3 and 12 months after transplanta-
tion (P<.01; Figure 2). Moreover, the BAL ET-1 concen-
trations were significantly greater in the patients with
BOS grade 2 or 3 than in those without BOS at 3 and 12
months after transplantation (P<.01 and P ¼ .02, respec-
tively; Figure 3, A). However, no significant differences
were seen in the BAL ET-1 concentrations when patients
with BOS grade 1 were compared with those without
BOS (Figure 3, A).
The serum ET-1 concentrations were significantly ele-
vated in those with BOS grade 1 to 3 compared with those
in the patients without BOS at 3 and 12 months after trans-
plantation (P<.01 and P<.001, respectively; Figure 3, B).
Also, no significant differences were found in the serum ET-
1 concentrations when patients with BOS grades 1 to 3 were
compared (Figure 3, B). Moreover, no significant difference
was found when the repeated ET-1 measurements at 3 and
12 months after transplantation were compared. However,
the pretransplant serum ET-1 level was significantly greater
than the ET-1 concentrations at 3 and 12 months after trans-
plantation in all patients (P<.001).
The serum and BAL ET-1 concentrations correlated sig-
nificantly with each other in the study cohort (rs ¼ 0.63;
P<.01 at 3 months and rs ¼ 0.72; P<.002 at 12 months
after transplantation). Moreover, serum ET-1 correlateddiovascular Surgery c Volume 140, Number 6 1425
FIGURE 3. Endothelin-1 (ET-1) bronchoalveolar lavage (BAL) and serum concentrations were elevated in patients with bronchiolitis obliterans syndrome
(BOS). (A) BALET-1 concentrations at 3 and 12months (m.) after transplant were significantly increased in patients with BOS grades 2 and 3 but not grade 1
compared with those without BOS. (B) Serum ET-1 concentrations at 3 and 12 months were significantly elevated in those with BOS grade 1 to 3 compared
with those in patients without BOS and healthy controls. *P ¼ .02, yP<.01, zP<.001.
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Xsignificantly with the frequency of previous acute allograft
rejection episodes: classification A (rs ¼ 0.21; P ¼ .024)
and B (rs ¼ 0.46; P < .0001). However, no difference
was seen in the serum ET-1 levels among the study
patients regarding their history of infection or type of
immunosuppression.
Logistic regression analysis indicated that serum ET-1 at
3 months after transplantation predicts for BOS (OR, 2.9;
95% CI, 1.01–8.52; P<.001; Table 2). Moreover, the se-
rum ET-1 level measured after BOS development diagnosed
BOS grade 1 to 3 as opposed to no BOS (OR, 3.9; 95% CI,
1.42–10.80; P ¼ .008; Table 2). In addition, logistic regres-
sion analysis showed that patients with repeated acute rejec-
tion episodes were at a greater risk of developing BOS:
grade A (OR, 5.1; 95% CI, 1.99–12.94; P<.001) and grade
B (OR, 3.4; 95% CI, 1.82–6.72; P<.001; Table 2).
DISCUSSION
Although the etiology of BOS is not clearly understood,
the existing evidence of the role of small airway inflamma-
tion and acute rejection in BOS5 strongly suggests that the
cellular and humoral storm directed to the allograft is cru-
cial in BOS. Several growth factors and cytokines, includ-
ing ET-1, have been suggested to be involved in BOS
pathogenesis.16-18 ET-1 possesses potent fibrogenic, vaso-
active, and inflammatory properties that enable it to contrib-
ute to airway remodeling. In addition, ET-1 is thought to be
involved in several inflammatory airway diseases such as
asthma, bronchiectasis, and idiopathic lung fibrosis.8,9
Accordingly, experimental models have shown that ET-1
might be associated with BO.11 Furthermore, an earlier
work reported that ET-1 production in response to lung al-
lograft injury starts early in donors and might influence
the development of primary graft dysfunction, a known
risk factor of BOS.13 Two key findings in the present study
strongly suggest the role of ET-1 in clinical BO. First, the1426 The Journal of Thoracic and Cardiovascular Surpretransplant serum ET-1 level was significantly increased
in patients who developed BOS. Second, the patients who
developed BOS showed persistent post-transplant ET-1 ele-
vation in their serum, BAL, and pulmonary tissue. Third,
the serum ET-1 levels correlated with those in the BAL of
the lung recipients, indicating that the lung allograft was
the main source of circulating ET-1.
The pretransplant serum ET-1 was significantly elevated
compared with the post-transplant serum ET-1 in all study
patients. One explanation might be that pretransplant ET-
1 level represents an inflammatory response to the massive
pulmonary damage owing to the underlying lung disease.
Importantly, our current data revealed that the pretransplant
ET-1 is a useful predictor of BOS, independent of acute re-
jection. Furthermore, patients with elevated pretransplant
ET-1 levels were associated with elevated post-transplant
ET-1 levels and more acute rejection episodes. This phe-
nomenon could have been because ET-1 contributes to en-
dothelial necrosis, as shown previously in a transplanted
tracheal model. The latter response can trigger immune re-
actions and acute rejection episode.11 The acute rejection,
in turn, contributes to additional allograft damage and upre-
gulation of ET-1 production. It has also been shown that
nonimmunologic factors and cyclosporine treatment could
contribute to ET-1 upregulation in lung transplant recipi-
ents.20 However, the association among ET-1, cyclosporine,
and BOS calls for additional studies. Taking together, the
repeated immunologic and nonimmunologic insults against
the lung graft might result in elevation of pulmonary ET-1
that contributes to BO development.
TBB remains the reference standard diagnostic tool for
BO. However, TBB is invasive and can deliver false-
negative results owing to the patchy nature of BO.15 There-
fore, a diagnostic biomarker, preferably a serum biomarker,
could facilitate the diagnosis of BO and reduce patient mor-
bidity. We have recently reported that BAL matrixgery c December 2010
Salama et al Cardiothoracic Transplantationmetalloproteases could be a diagnostic marker of BO19;
however, serum biomarkers are less invasive. The present
results have shown that serum ET-1 can serve as an indepen-
dent and noninvasive serum biomarker for the early predic-
tion of BOS and its monitoring in lung transplant recipients.
This assumption calls for randomized prospective studies,
which we are planning at our center.
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